MiNK Therapeutics’ (INKT) Buy Rating Reiterated at HC Wainwright

MiNK Therapeutics (NASDAQ:INKT)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $35.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 336.41% from the company’s previous close.

MiNK Therapeutics Price Performance

Shares of INKT traded down $0.50 during midday trading on Tuesday, hitting $8.02. 10,271 shares of the company traded hands, compared to its average volume of 15,557. The stock has a 50-day moving average of $8.93 and a 200-day moving average of $7.74. MiNK Therapeutics has a one year low of $4.56 and a one year high of $19.00. The firm has a market cap of $31.78 million, a P/E ratio of -2.06 and a beta of 0.16.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.12). Sell-side analysts forecast that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.